BRPI0920496A2 - derivados substituídos de pirimidina etriazina - Google Patents
derivados substituídos de pirimidina etriazinaInfo
- Publication number
- BRPI0920496A2 BRPI0920496A2 BRPI0920496A BRPI0920496A BRPI0920496A2 BR PI0920496 A2 BRPI0920496 A2 BR PI0920496A2 BR PI0920496 A BRPI0920496 A BR PI0920496A BR PI0920496 A BRPI0920496 A BR PI0920496A BR PI0920496 A2 BRPI0920496 A2 BR PI0920496A2
- Authority
- BR
- Brazil
- Prior art keywords
- etriazine
- pyrimidine derivatives
- substituted pyrimidine
- substituted
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08018514 | 2008-10-23 | ||
PCT/EP2009/007568 WO2010046109A1 (de) | 2008-10-23 | 2009-10-22 | Pyrimidin- und triazin- sulfonamidderivate als bradykinin b1 rezeptor (b1r) inhibitoren zur behandlung von schmerz |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0920496A2 true BRPI0920496A2 (pt) | 2019-09-24 |
Family
ID=40386034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0920496A BRPI0920496A2 (pt) | 2008-10-23 | 2009-10-22 | derivados substituídos de pirimidina etriazina |
Country Status (17)
Country | Link |
---|---|
US (1) | US8269000B2 (pt) |
EP (1) | EP2356101B1 (pt) |
JP (1) | JP2012506396A (pt) |
AR (1) | AR073919A1 (pt) |
AU (1) | AU2009306723A1 (pt) |
BR (1) | BRPI0920496A2 (pt) |
CA (1) | CA2741349A1 (pt) |
CY (1) | CY1113942T1 (pt) |
DK (1) | DK2356101T3 (pt) |
ES (1) | ES2409109T3 (pt) |
HR (1) | HRP20130423T1 (pt) |
MX (1) | MX2011004211A (pt) |
PL (1) | PL2356101T3 (pt) |
PT (1) | PT2356101E (pt) |
SI (1) | SI2356101T1 (pt) |
TW (1) | TW201022267A (pt) |
WO (1) | WO2010046109A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
EP2825694A4 (en) | 2012-03-16 | 2016-04-20 | Impossible Foods Inc | AFFINITY REAGENTS FOR PROTEIN CLEANING |
US20160068486A1 (en) * | 2013-04-22 | 2016-03-10 | Reuter Chemische Apparatebau Kg | Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
CN109265395B (zh) * | 2018-09-21 | 2021-10-26 | 中国烟草总公司郑州烟草研究院 | 一种二氯喹啉酸半抗原与抗原的制备方法及应用 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003505384A (ja) * | 1999-07-15 | 2003-02-12 | ファーマコピーア,インコーポレーティッド | ブラジキニンb1受容体アンタゴニスト |
WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
WO2007140383A2 (en) | 2006-05-30 | 2007-12-06 | Neurogen Corporation | Spirocyclic sulfonamides and related compounds |
MX2009003382A (es) | 2006-09-29 | 2009-04-08 | Gruenenthal Gmbh | Derivados de sulfonamidas sustituidos. |
EP2086935A1 (de) * | 2006-10-16 | 2009-08-12 | Grünenthal GmbH | Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren |
-
2009
- 2009-09-11 TW TW098130643A patent/TW201022267A/zh unknown
- 2009-10-22 DK DK09740860.3T patent/DK2356101T3/da active
- 2009-10-22 AR ARP090104060A patent/AR073919A1/es not_active Application Discontinuation
- 2009-10-22 BR BRPI0920496A patent/BRPI0920496A2/pt not_active IP Right Cessation
- 2009-10-22 CA CA2741349A patent/CA2741349A1/en not_active Abandoned
- 2009-10-22 ES ES09740860T patent/ES2409109T3/es active Active
- 2009-10-22 EP EP09740860A patent/EP2356101B1/de not_active Not-in-force
- 2009-10-22 PT PT97408603T patent/PT2356101E/pt unknown
- 2009-10-22 JP JP2011532539A patent/JP2012506396A/ja not_active Withdrawn
- 2009-10-22 SI SI200930539T patent/SI2356101T1/sl unknown
- 2009-10-22 MX MX2011004211A patent/MX2011004211A/es not_active Application Discontinuation
- 2009-10-22 WO PCT/EP2009/007568 patent/WO2010046109A1/de active Application Filing
- 2009-10-22 AU AU2009306723A patent/AU2009306723A1/en not_active Abandoned
- 2009-10-22 PL PL09740860T patent/PL2356101T3/pl unknown
- 2009-10-23 US US12/604,691 patent/US8269000B2/en not_active Expired - Fee Related
-
2013
- 2013-04-23 CY CY20131100330T patent/CY1113942T1/el unknown
- 2013-05-14 HR HRP20130423AT patent/HRP20130423T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010046109A1 (de) | 2010-04-29 |
HRP20130423T1 (en) | 2013-06-30 |
EP2356101B1 (de) | 2013-02-27 |
CY1113942T1 (el) | 2016-07-27 |
JP2012506396A (ja) | 2012-03-15 |
TW201022267A (en) | 2010-06-16 |
EP2356101A1 (de) | 2011-08-17 |
PL2356101T3 (pl) | 2013-07-31 |
PT2356101E (pt) | 2013-06-03 |
US20100173889A1 (en) | 2010-07-08 |
DK2356101T3 (da) | 2013-05-27 |
SI2356101T1 (sl) | 2013-04-30 |
US8269000B2 (en) | 2012-09-18 |
ES2409109T3 (es) | 2013-06-25 |
AR073919A1 (es) | 2010-12-09 |
CA2741349A1 (en) | 2010-04-29 |
AU2009306723A1 (en) | 2010-04-29 |
MX2011004211A (es) | 2011-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
ES2465673T9 (es) | Derivados de pirimidina | |
BRPI0920496A2 (pt) | derivados substituídos de pirimidina etriazina | |
BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
BRPI0914662A2 (pt) | derivados de triazinona substituída | |
BRPI0812155A2 (pt) | derivados de espiroindolinona | |
BRPI0817935A2 (pt) | Derivados de biarila | |
BRPI0906436A2 (pt) | Derivados de ftalazinona | |
BRPI0914301A2 (pt) | derivados de pirimidin-4-ona substituída | |
BRPI0909527A2 (pt) | derivados substituídos de 4-aminociclohexano | |
BRPI0923497A2 (pt) | derivados de piridazinona | |
BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
BRPI0812518A2 (pt) | Derivados de indazolamida | |
BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
BR112012008108A2 (pt) | derivados de xantina substituídos | |
DK2275414T3 (da) | Cyclopentylacrylamidderivat | |
ATE545635T1 (de) | Substituierte n-oxidpyrazinderivate | |
BRPI1013493A2 (pt) | composto de pirimidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |